Alleviation effect of mesalazine on intestinal mucosal inflammation in acute pancreatitis: a clinical randomized controlled trial

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR-IPR-15006398

Enrollment

Unknown

Registered

2015-05-13

Start date

2015-05-11

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

acute pancreatitis

Interventions

group of mesalazine:conventional medical management+mesalazine

control group:conventional medical management

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1) patients with acute pancreatitis; 2) 18-65 years old; 3) within 7 days since the onse.

Exclusion criteria

Exclusion criteria: 1) intestinal tumor; 2) non-pancreatic infection or sepsis caused by a second disease; 3)a medical history of immune deficiency,infalmmatory bowel disease,chronic diarrhea or constipation,or intestinal infection within one month; 4) patients with severe diseases of heart, liver, kidney, brain, or respiratory syetem; 5) long term usage of mesalazine; 6) women in pregnancy or lactation.

Design outcomes

Primary

Measure	Time frame
intestinal mucosal inflammation scoring;	—

Secondary

Measure	Time frame
intestinal mucosal microflora;inflammation index in the blood;	—

Countries

China

Contacts

Public ContactJing Li

melody224@163.com+86 18980606763

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026